NCT00730652View on ClinicalTrials.gov

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma

PHASE1WithdrawnINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2013

Conditions

Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.

Interventions

BIOLOGICAL

MDX-1411

Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.